Foam product should boost Leo Pharma’s US business
Leo Pharma has submitted an application to the FDA for a new product the company calls “the most effective psoriasis drug” it has ever developed. The drug is set to take center stage in the company’s US strategy.
BY STEFAN SINGH KAILAY
Leo Pharma dreams of reaching far more US patients than the company does at the moment and one of the ways to achieve that is to have a palette of products tailored to the individual needs of psoriasis patients, says sales and marketing chief Lars Olsen, adding that its newest drug, Enstillar, will play a prominent role in that regard.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma enters Japanese alliance
For abonnenter
Leo Pharma unfazed by biological competition
For abonnenter
Leo Pharma buys discovery from Danish hospital
For abonnenter
